TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7623249
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment with gingival flap surgery with barrier membrane alone
Study: 2533041
Drug: Ponalrestat (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponalrestat (600 mg single dose)
Study: 779058
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tilidine hydrochloride
Study: 28121722
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of EPA and 400 mg of DHA per day for 18 weeks
Study: 28121722
Drug: Soybean oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil capsules (placebo) per day for 18 weeks
Study: 9748131
Drug: 3F8 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3F8 treatment
Study: 9919895
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg daily for 2 weeks
Study: 2493756
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium (2 mg per dose) by MDI
Study: 1097921
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment at placebo points
Study: 30045159
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PDC and GC adherence
Study: 23219310
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 500mg orally twice daily for 28 days
Study: 9418642
Drug: Intraarterial chemotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial chemotherapy, local irradiation, limb salvage surgery, prophylactic whole lung irradiation
Study: 9418642
Drug: Histologic response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Histologic response to preoperative multidisciplinary therapy
Study: 31713082
Drug: Dextrose injection
Normalized name: Dextrose Injection
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose injection (1% lidocaine with 20% dextrose, 1 mL)
Study: 31713082
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection (1% lidocaine with saline, 1 mL)
Study: 28029114
Drug: 400 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 µg folic acid and 500 µg vitamin B12 supplementation
Study: 25011384
Drug: Combination exercise
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination exercise group
Study: 11563205
Drug: In-home assessment
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-home assessment with individualized treatment plan including exercise program
Study: 11563205
Drug: In-home assessment
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-home assessment with individualized treatment plan including exercise program (for subjects with more than 2 falls in the 3 months preceding study entry)
Study: 3043949
Drug: Isoconazole cream,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoconazole cream, solution, and spray (once or twice daily)
Study: 27670154
Drug: Daily dose
Normalized name: LENVIMA 8mg Daily Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of cholecalciferol (400 IU)
Study: 27670154
Drug: Single high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-dose cholecalciferol (50,000 IU)
Study: 21477053
Drug: Sex under
Normalized name: Depend Fresh Protection Maximum Absorbency with Tabs Unisex Underwear (Large)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex under the influence of drugs or alcohol
Study: 21477053
Drug: No influence
Approvals — FDA: no, EMA: no, PMDA: no
Description: No influence of drugs or alcohol
Study: 19055791
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg oral salmon calcitonin (sCT) morning dose at 8:00
Study: 19055791
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg oral salmon calcitonin (sCT) pre-dinner dose at 17:00
Study: 19055791
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg oral salmon calcitonin (sCT) evening dose at 22:00
Study: 11887831
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy and SERMs (raloxifene)
Study: 8077324
Drug: Low insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low insulin infusion (742 +/- 212 pmol/L)
Study: 8077324
Drug: High insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High insulin infusion (3360 +/- 710 pmol/L)
Study: 8077324
Drug: Both insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both insulin infusions
Study: 3608350
Drug: Torasemide (intermediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide (intermediate dose between 10 and 20 mg)
Study: 3608350
Drug: Probenecid pretreatment
Normalized name: Probenecid
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probenecid pretreatment with Torasemide 20 mg
Study: 30299202
Drug: TCZ-SC qw
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCZ-SC qw monotherapy
Study: 23701202
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of CQ (600 mg on days 1-2, 300 mg on day 3) and TQ (450 mg on days 2 and 3)
Study: 23701202
Drug: TQ alone
Normalized name: TQS-168
DrugBank: TQS-168 (DB18108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ alone (450 mg on days 2 and 3)
Study: 23701202
Drug: CQ alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQ alone (600 mg on days 1-2, 300 mg on day 3)
Study: 21778609
Drug: Control: No
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: No surface treatment
Study: 19712032
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (indication‐based guidelines for prescription of broad‐spectrum antimicrobials)
Study: 16542207
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tramadol sustained release every 12 h for 12 weeks
Study: 15145633
Drug: Rectal artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rectal artesunate (single dose of about 10 mg/kg)
Study: 15145633
Drug: Parenteral quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral quinine (10 mg/kg at 0, 4, and 12 h)
Study: 15145633
Drug: Rectal artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rectal artesunate and parenteral quinine
Study: 11180036
Drug: Diltiazem (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (120 mg) coadministration with Sirolimus (10 mg)
Study: 11180036
Drug: Sirolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (10 mg) alone
Study: 11180036
Drug: Diltiazem (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (120 mg) alone
Study: 9597123
Drug: IL-1Ra treatment
Normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IL-1Ra treatment for six months
Study: 2452393
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (3 x COPP + ABVD)
Study: 2452393
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (3 x COPP + ABVD) with consolidation by radiotherapy (20 Gy IF)
Study: 2452393
Drug: Including salvage
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Including salvage therapy (radiotherapy in case of persisting nodal disease; chemotherapy with 4 x CEVD in case of persisting disseminated disease)
Study: 30974039
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection (100 U in 10 points in the distal part of the esophageal wall)
Study: 25550338
Drug: methotrexate monotherapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate monotherapy followed by add-on therapy with sulfasalazine and hydroxychloroquine
Study: 25550338
Drug: methotrexate monotherapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate monotherapy followed by add-on therapy with infliximab
Study: 25550338
Drug: initial methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: initial methotrexate therapy
Study: 25550338
Drug: anti-CCP antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-CCP antibodies
Study: 25550338
Drug: anti-cVim antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-cVim antibodies
Study: 19615804
Drug: AST‐120 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST‐120 (6 g/d)
Study: 19615804
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (low-protein diet and antihypertensive medication)
Study: 15131439
Drug: Subset with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subset with somatization disorder in injection group
Study: 9818106
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg ropivacaine
Study: 9818106
Drug: 187.5 mg
Normalized name: terbinafine 187.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 187.5 mg ropivacaine
Study: 9818106
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ropivacaine
Study: 9818106
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg bupivacaine
Study: 2651190
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg after dinner
Study: 28937830
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg per day for 2 months)
Study: 26561628
Drug: Low-fat, high-complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat, high-complex carbohydrate (LFHCC) diet supplemented with long-chain n-3 polyunsaturated fatty acids (1.2 g/d)
Study: 23832463
Drug: 4000 UI/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 UI/week i.v. of epoetin alfa, beta or any other epoetin in equivalent doses
Study: 23832463
Drug: 18000 UI/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18000 UI/week i.v. of epoetin alfa, beta or any other epoetin in equivalent doses
Study: 19349313
Drug: Single-dose (21-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose (21- or 35-mg) nicotine patch
Study: 9413736
Drug: buspirone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: buspirone (45 mg)
Study: 7741805
Drug: High-dose vecuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vecuronium (0.3 mg kg ‐1)
Study: 7741805
Drug: Suxamethonium (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium (1.0 mg kg ‐1)
Study: 3948472
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of cholestyramine 4 hours after HCTZ
Study: 3948472
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of cholestyramine (-24, -12, and +4 hours after HCTZ)
Study: 27384042
Drug: LEDT (photobiomodulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEDT (photobiomodulation therapy using cluster light‐emitting diodes; 104 diodes; wavelength 660 and 850 nm; energy density 1.5 and 4.5 J/cm2; energy 60 J at each point; total energy delivered 600 J)
Study: 23131207
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg dose of hemagglutinin (HA) antigen
Study: 23131207
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg dose of hemagglutinin (HA) antigen
Study: 12413434
Drug: Staphylococcus toxoid
Normalized name: Staphylococcus toxoid vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staphylococcus toxoid (SB) injections (0.1 ml to 1.0 ml weekly for 6 months)
Study: 12413434
Drug: Staphylococcus toxoid
Normalized name: Staphylococcus toxoid vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staphylococcus toxoid (SB) injections
Study: 1699088
Drug: Aprotinin treatment
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin treatment during cardiopulmonary bypass
Study: 16256784
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment during cardiopulmonary bypass
Study: 113627
Drug: Further treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Further treatment attempts after initial therapy (Gp R)
Study: 113627
Drug: Further treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Further treatment attempts after initial therapy (Gp S)
Study: 113627
Drug: Further treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Further treatment attempts after initial therapy (Gp R/S)
Study: 31896121
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake (total and intravenous)
Study: 25547632
Drug: Cognitive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive and motor stimulation interventions (CMSI) administered by a single care provider
Study: 23399084
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone pulses plus mycophenolate mofetil
Study: 11076325
Drug: 4-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day antibiotic therapy
Study: 19097848
Drug: 7-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day antibiotic therapy
Study: 9103686
Drug: Microgynon (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microgynon (combined pill)
Study: 1568716
Drug: 3 million
Normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 million units of recombinant interferon‐alpha three times weekly for 12 weeks
Study: 7259326
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) infusion
Study: 31941260
Drug: Terlipressin (1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (1mg intravenous drip or static push every 6-12 hours for more than 5 days)
Study: 29866141
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive behavioral therapy (CBT)
Study: 27153076
Drug: Ergonomic intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ergonomic intervention (details on dosage and duration not specified)
Study: 18479353
Drug: Pamidronate (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (60 mg intravenously, 2 weeks before bed rest)
Study: 12072899
Drug: Pamidronate (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (60 mg)
Study: 15854173
Drug: 2.4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g/day of mesalazine
Study: 15854173
Drug: 1.2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g/day of mesalazine
Study: 10604820
Drug: Cotrimoxazole (TMP/SMX)
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotrimoxazole (TMP/SMX) 4 mg/kg TMP/20 mg/kg SMX at two divided doses for 5 days
Study: 1685572
Drug: Controlled-release remoxipride
Normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release remoxipride (REM-CR), 361 mg daily
Study: 1685572
Drug: Immediate-release remoxipride
Normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release remoxipride (REM-IR), 332 mg daily
Study: 1685572
Drug: Haloperidol, 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol, 12.5 mg daily
Study: 31780765
Drug: Amfepramone (AFP)
Normalized name: amfepramone
DrugBank: Diethylpropion (DB00937)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amfepramone (AFP) 75 mg single dose
Study: 21823222
Drug: Step 1
Normalized name: Nicotine Patch Step 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step 1 diet supplemented with soy food (SFD; 50 mg isoflavones per day)
Study: 11528571
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis (AP) vaccine
Study: 11528571
Drug: Licensed meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed meningococcal vaccine (MN)
Study: 31140654
Drug: Day-and-night hybrid
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day-and-night hybrid closed-loop insulin delivery using Cambridge FlorenceM system
Study: 14616415
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg once daily)
Study: 27310328
Drug: 2D regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2D regimen (ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily)
Study: 27310328
Drug: 3D regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D regimen (ombitasvir/paritaprevir/ritonavir and dasabuvir 250 mg twice daily)
Study: 22653713
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of calcium (as calcium carbonate)
Study: 22653713
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of calcium
Study: 20460997
Drug: Dexmedetomidine (0.4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.4, 0.6, and 0.8 ng/ml) as an adjunct to propofol-based TIVA
Study: 20460997
Drug: Dexmedetomidine (0.6-0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.6-0.8 ng/ml) as an adjunct to propofol-based TIVA
Study: 15699227
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing extracted soy isoflavones
Study: 8996743
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefotiam + 500 mg metronidazole
Study: 8996743
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefotiam + 500 mg metronidazole
Study: 8487059
Drug: Immediate-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release morphine (IRM) solution (20 mg/mL)
Study: 8487059
Drug: Sustained-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release morphine (SRM) formulation (30 mg)
Study: 2512801
Drug: Moderate weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate weight gain (4-6 g.kg-1.d-1) - MG group
Study: 2512801
Drug: Rapid weight
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid weight gain (12-16 g.kg-1.d-1) - RG group
Study: 19223278
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aerobic exercise (20 min/day)
Study: 19223278
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose aerobic exercise (40 min/day)
Study: 9010986
Drug: Dolasetron mesilate
Normalized name: Dolasetron mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron mesilate 1.2 mg/kg
Study: 9010986
Drug: Metoclopramide 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 7 mg/kg
Study: 8054248
Drug: Ethanol (0.80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.80 g/kg body weight)
Study: 10639202
Drug: Pulsed nebulization
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed nebulization (2 mL of 0.5 mg mL(-1) or 2 mL of 0.25 mg mL(-1) budesonide)
Study: 10639202
Drug: Breath-synchronized nebulization
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breath-synchronized nebulization (2 mL of 0.5 mg mL(-1) or 2 mL of 0.25 mg mL(-1) budesonide)
Study: 10639202
Drug: Constant output
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant output nebulization (2 mL of 0.5 mg mL(-1) or 2 mL of 0.25 mg mL(-1) budesonide)
Study: 8347899
Drug: Double-drug (methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-drug (methylprednisolone and azathioprine)
Study: 8347899
Drug: Triple-drug (methylprednisolone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug (methylprednisolone, azathioprine, and cyclosporine)
Study: 28988341
Drug: Axitinib monotherapy
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib monotherapy (AXI)
Study: 27529317
Drug: Glucose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose group (infused with acetated Ringer's solution with glucose at 2 mg/kg/min)
Study: 27529317
Drug: No glucose
Normalized name: No glucose hemofiltration solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: No glucose group (infused with acetated Ringer's solution without glucose)
Study: 24841795
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose intravenous ozanezumab (0.01, 0.1, 1, 5, or 15 mg/kg)
Study: 24841795
Drug: Repeat doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat doses of intravenous ozanezumab (0.5, 2.5, or 15 mg/kg)
Study: 24841795
Drug: Ozanezumab (0.01-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanezumab (0.01-15 mg/kg)
Study: 24841795
Drug: Repeat dose
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat dose 15 mg/kg ozanezumab